AI scans 3000 liver cancer patients to pick best therapy
NCT ID NCT07368530
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study analyzed medical images and data from 3000 patients with advanced liver cancer that cannot be removed by surgery. Researchers used an AI technique called radiomics to see if they could identify which patients would respond better to one of two standard treatments: TACE (a procedure that blocks the tumor's blood supply) or HAIC (chemotherapy delivered directly to the liver). The goal is to develop a tool that helps doctors personalize treatment decisions, but because this is a retrospective study looking at past data, it cannot prove that the AI model will work for future patients.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- What this could lead to
- If successful, this could help doctors choose the best liver cancer treatment for each patient, improving outcomes without a one-size-fits-all approach.
- What could go wrong
- This is a retrospective study, meaning it looks back at old data, so it cannot prove cause and effect. The AI model may not work as well in new patients or other hospitals.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BCLC STAGE B HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
The First Affiiated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, 510080, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Freeze-and-Heat attack: could a new device boost liver cancer treatment?
- Liver cancer study tracks Real-World treatments and survival
- Liver cancer trial tests combo therapy against single drug
- Radioactive beads aim to shrink inoperable liver tumors
- Radioactive beads offer new hope for inoperable liver cancer
- Triple therapy boosts survival in tough liver cancer cases